“This research is taking promising steps towards a new one-of-a-kind therapy which targets tau, a damaging protein in the brains of people living with Alzheimer’s, preventing it from clumping together,” said Richard Oakley, associate director of research and innovation at the Alzheimer’s Society UK, which funded the research.

A team of researchers has reported a significant advance in Alzheimer’s treatment. Their candidate drug, RI-AG03, attacks the accumulation of tau proteins—crucial to the disease’s progression—in lab and animal tests.

Researchers have hailed a promising breakthrough in the development of drugs to treat Alzheimer’s disease. For the first time, scientists have created a drug that works by targeting both key areas of a protein linked to the disease.